Nautilus Biotechnology to Present at EuPA and AACR Meetings
April 04 2022 - 8:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced presentations at the
following leading scientific and medical conferences.
XIV Annual Congress of the European Proteomics
Association (EuPA): Parag Mallick, Ph.D., co-founder and
Chief Scientist of Nautilus, is scheduled to present at EuPA, or
the Proteomic Forum, in Leipzig, Germany on Wednesday, April 6,
2022 at 1:30 p.m. CET (4:30 a.m. PT / 7:30 a.m. ET). Dr. Mallick’s
presentation titled “Development of a Novel, Single-Molecule
Proteomics Analysis Platform” will be held during the Emerging
Technologies symposium in Room Händel.
American Association for Cancer Research (AACR) Annual
Meeting: Greg Kapp, Ph.D., Associate Director of
Applications Development at Nautilus, will present a poster titled
“Toward comprehensive, single-molecule proteomics: Protein
identification by short-epitope mapping” on Wednesday, April 13,
2022 at 9:00 a.m. CT (7:00 a.m. PT / 10:00 a.m. ET) in New Orleans,
LA. Dr. Kapp’s poster presentation will take place in Section 21
during Session PO.CH03.01 - Proteomics, Signaling Networks, and
Biomarker Discovery. The embargoed abstract will be released on
Friday, April 8, 2022 at 12:00 p.m. CT (10:00 a.m. PT / 1:00 p.m.
ET) to registered meeting attendees.
About Nautilus Biotechnology, Inc.With its
corporate headquarters in Seattle and its research and development
headquarters in the San Francisco Bay Area, Nautilus is a
development stage life sciences company creating a platform
technology for quantifying and unlocking the complexity of the
proteome. Nautilus’ mission is to transform the field of proteomics
by democratizing access to the proteome and enabling fundamental
advancements across human health and medicine. To learn more about
Nautilus, visit www.nautilus.bio.
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of federal securities laws.
Forward-looking statements in this press release include, but are
not limited to, statements regarding Nautilus’ expectations with
respect to the suitability of the Nautilus product platform to
investigate proteins and proteoforms; and expectations with respect
to the functionality and performance of Nautilus’ product platform,
its potential impact on pharmaceutical development and drug
discovery. These statements are based on numerous assumptions
concerning the development of Nautilus’ products and target markets
and involve substantial risks, uncertainties and other factors that
may cause actual results to be materially different from the
information expressed or implied by these forward-looking
statements. Risks and uncertainties that could materially affect
the accuracy of Nautilus’ assumptions and its ability to achieve
the forward-looking statements set forth in this press release
include (without limitation) the following: Nautilus’ product
platform is not yet commercially available and remains subject to
significant scientific and technical development, which is
inherently challenging and difficult to predict, particularly with
respect to highly novel and complex products such as those being
developed by Nautilus. Even if our development efforts are
successful, our product platform will require substantial
validation of its functionality and utility in life science
research. In the course of Nautilus’ scientific and technical
development and associated product validation and
commercialization, we may experience material delays as a result of
unanticipated events. We cannot provide any guarantee or assurance
with respect to the outcome of our development, collaboration, and
commercialization initiatives or with respect to their associated
timelines. For a more detailed description of additional risks and
uncertainties facing Nautilus and its development efforts,
investors should refer to the information under the caption “Risk
Factors” in the Registration Statement on Form S-1 filed with the
SEC as well as in our Annual Report on Form 10-K filed for the year
ended December 31, 2021. The forward-looking statements in this
press release are as of the date of this press release. Except as
otherwise required by applicable law, Nautilus disclaims any duty
to update any forward-looking statements. You should, therefore,
not rely on these forward-looking statements as representing our
views as of any date subsequent to the date of this press
release.
Disclosure InformationNautilus uses filings
with the Securities and Exchange Commission, its website
(www.nautilus.bio), press releases, public conference calls, public
webcasts, and its social media accounts as means of disclosing
material non-public information and for complying with Regulation
FD. Therefore, Nautilus encourages investors, the media, and others
interested in Nautilus to review the information it makes public in
these locations, as such information could be deemed to be material
information.
Media Contactpress@nautilus.bio
Investor
Contactinvestorrelations@nautilus.bio
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Apr 2023 to Apr 2024